Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5814.

https://doi.org/10.1182/blood-2025-5814

Published: 2025

Journal Articles

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Blood (2025) 146 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2025-5945

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Journal Articles

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Blood (2025) 146 (Supplement 1): 804.

https://doi.org/10.1182/blood-2025-804

Published: 2025

Journal Articles

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Blood (2025) 146 (Supplement 1): 699.

https://doi.org/10.1182/blood-2025-699

Published: 2025

Journal Articles

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Blood (2025) 146 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2025-4543

Published: 2025

Journal Articles

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

Heta Patel, Luca Paruzzo, Oxana Megherea, Matthew Ho, Thomas Luo, Dan Vogl, Shivani Kapur, Adam Waxman, Federico Stella, Alberto Carturan, Martina Pucillo, Antonio Imparato, Edward Stadtmauer, Alfred Garfall, Adam Cohen, Marco Ruella, Sandra Susanibar-Adaniya

Blood (2025) 146 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2025-3995

Published: 2025

Journal Articles

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Blood (2025) 146 (Supplement 1): 7189.

https://doi.org/10.1182/blood-2025-7189

Published: 2025

Journal Articles

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Brian D Friend, MD, Larisa Broglie, MD MS, Brent Logan, PhD, Caitrin Fretham, MPH, Gary J. Schiller, MD, Bipin N. Savani, MD, Edward Stadtmauer, Saurabh Chhabra, MD, Marcelo C. Pasquini, MDMS, Monica Thakar, MD, Mohamed Sorror, MD MSc

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-140778

Published: 2020

Journal Articles

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137743

Published: 2020

Journal Articles

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Colleen Timlin, PharmD, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, Selina Luger, MD, Jacqueline Smith, MSN, CRNP, Edward Stadtmauer, David L. Porter, MD

Blood (2018) 132 (Supplement 1): 5696.

https://doi.org/10.1182/blood-2018-99-111550

Published: 2018

Journal Articles

Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)

Philip L. McCarthy, MD, Paul Richardson, Vera Suman, Miranda Cooper, Owain Saunders, Sujith Dhanasiri, Sergio Giralt, MD, Kenneth Anderson, MD, Edward Stadtmauer, Sarah A. Holstein, MD PhD

Blood (2018) 132 (Supplement 1): 4737.

https://doi.org/10.1182/blood-2018-99-113001

Published: 2018

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma

Lilly Wilson, Adam D. Cohen, MD, Brendan M. Weiss, MD, Dan T. Vogl, MD, Alfred L. Garfall, MD, Donna L. Capozzi, PharmD, Patricia Mangan, MSN, CRNP, Mary Sanchez, MSN, CRNP, Colleen Erb, MSN, CRNP, Edward Stadtmauer, MD

Blood (2016) 128 (22): 2119.

https://doi.org/10.1182/blood.V128.22.2119.2119

Published: 2016

Journal Articles

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

Jatin Shah, Ruben Niesvizky, MD, Edward Stadtmauer, Robert M. Rifkin, James Berenson, MD, Jesus G. Berdeja, MD, Jeff P. Sharman, MD, Roger Lyons, Zandra Klippel, MD, Hansen Wong, Yu-Lin Chang, Saad Usmani

Blood (2015) 126 (23): 378.

https://doi.org/10.1182/blood.V126.23.378.378

Published: 2015

Journal Articles

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Blood (2012) 120 (14): 2817–2825.

https://doi.org/10.1182/blood-2012-05-425934

Published: 2012

Includes: Supplemental data

Journal Articles

A Comparison of Two Induction Regimens for Older Patients with Acute Lymphoblastic Leukemia: Daunorubicin, Vincristine and Prednisone (DVP) is Worth Considering

Daniel Landsburg, David Porter, Edward Stadtmauer, Alison Loren, Donald Tsai, Noelle Frey, Steven Goldstein, Elizabeth Hexner, Sunita Dwivedy Nasta, Alexander Perl, Jennifer Davis, Selina Luger

Blood (2010) 116 (21): 3252.

https://doi.org/10.1182/blood.V116.21.3252.3252

Published: 2010

Journal Articles

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Jennifer McQuade, MD, Tahamtan Ahmadi, MD, PhD, David Porter, Noelle Frey, Alison Wakoff Loren, MD, MS, Steven C. Goldstein, MD, Jakub Svoboda, MD, Edward Stadtmauer, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2010) 116 (21): 3570.

https://doi.org/10.1182/blood.V116.21.3570.3570

Published: 2010

Journal Articles

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Blood (2010) 116 (21): 985.

https://doi.org/10.1182/blood.V116.21.985.985

Published: 2010

Journal Articles

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Brian J. Bolwell, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Richard T. Maziarz, MD, Ivana N Micallef, MD, Sachin Marulkar, MBBS, MPH, Pritesh Gandhi, PharmD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3224.

https://doi.org/10.1182/blood.V114.22.3224.3224

Published: 2009

Journal Articles

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Auayporn P. Nademanee, MD, Edward Stadtmauer, MD, Ivana N Micallef, MD, Patrick Stiff, MD, Sachin Marulkar, MBBS, MPH, Gary C Calandra, M.D., Ph.D., John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3230.

https://doi.org/10.1182/blood.V114.22.3230.3230

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)

Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

A Comparison of Two Induction Regimens for Older Patients with Acute Lymphoblastic Leukemia: Daunorubicin, Vincristine and Prednisone (DVP) is Worth Considering

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only